Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
BCL6 Antibody
NCTP00651
Description: Rabbit polyclonal to human BCL6
Application: ELISA, WB
Reactivity: Human
Catalog #: NCTP00651
$360
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human. Other species not tested. |
| Isotype | IgG |
| Immunogen | 16 aa peptide near the C terminal of human BCL6 |
| Accession # | P41182 |
| Alternative Names | B-cell lymphoma 6 protein; BCL-6; B-cell lymphoma 5 protein; BCL-5; Protein LAZ-3; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51; BCL5; LAZ3; ZBTB27; ZNF51 |
| Purification | Purified by peptide affinity column. |
| Formulation | Lyophilized with 1% BSA and 0.02% NaN3. |
| Size | 100µg/200µl |
| APPLICATION | |
| ELISA | 1:20,000 – 1:80,000 |
| Western Blot | 1:200 – 1:1,000 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Seki,R., Ohshima,K., Fujisaki,T., et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 100 (10), 1842-1847 (2009). |